Home > Diagnosis and Treatment > Regimen selection > DESCOVY® > Efficacy and resistance

Efficacy and resistance

The clinical evidence to support DESCOVY®▼ (emtricitabine / tenofovir alafenamide) in combination with other antiretroviral agents for the treatment of HIV is based on studies conducted with FTC and TAF when given with boosted EVG as the fixed-dose combination tablet E/C/F/TAF,1-5 and data from a phase 3 trial in virologically suppressed adults with HIV infection. 6-8

HIV.eu is a site designed for healthcare professionals.

Continue to site Visit patient site

You are now leaving www.hiv.eu and visiting a new site which is not owned or controlled by Gilead Sciences. Gilead Sciences is therefore not responsible for your interactions with the website or the information it provides.

Cancel Follow link
You are now leaving www.hiv.eu and visiting a new site which is not owned or controlled by Gilead Sciences. Gilead Sciences is therefore not responsible for your interactions with the website or the information it provides.